Peris Ketty, Micantonio Tamara, Fargnoli Maria Concetta, Lozzi Gian Piero, Chimenti Sergio
Department of Dermatology, University of L'Aquila, Italy.
J Am Acad Dermatol. 2006 Aug;55(2):324-7. doi: 10.1016/j.jaad.2006.04.004.
Imiquimod has been successfully used for treatment of various epithelial cutaneous neoplasms.
Our aim was to evaluate the efficacy and tolerability of imiquimod 5% cream for treatment of Bowen's disease and invasive squamous cell carcinoma (SCC) in patients who were unsuitable candidates for surgery.
Five Bowen's disease lesions and 7 invasive SCC lesions on 10 patients were treated with imiquimod once daily 5 times a week for a maximum of 16 weeks.
After 8 to 12 weeks of treatment, 4 of 5 Bowen's disease lesions (80%) and 5 of 7 invasive SCCs (71.4%) showed complete clinicopathologic regression. The remaining 3 lesions showed partial regression after 16 weeks of treatment. No recurrence has been detected after a follow-up period of 24 to 38 months (mean, 31 months).
The study is an open-label clinical trial on a small number of selected patients, with lack of excision with serial step sections.
Topical application of imiquimod 5% cream might represent an alternative topical treatment to surgery in selected cases of Bowen's disease and invasive SCC.
咪喹莫特已成功用于治疗各种上皮性皮肤肿瘤。
我们的目的是评估5%咪喹莫特乳膏治疗不适合手术的鲍温病和浸润性鳞状细胞癌（SCC）患者的疗效和耐受性。
对10例患者的5处鲍温病皮损和7处浸润性SCC皮损，每周5次，每日1次外用咪喹莫特，最长治疗16周。
治疗8至12周后，5处鲍温病皮损中的4处（80%）和7处浸润性SCC皮损中的5处（71.4%）显示临床病理完全消退。其余3处皮损在治疗16周后显示部分消退。随访24至38个月（平均31个月）未发现复发。
本研究是一项针对少数选定患者的开放标签临床试验，缺乏连续切片切除。
在选定的鲍温病和浸润性SCC病例中，外用5%咪喹莫特乳膏可能是手术之外的另一种局部治疗方法。
